Lexicon Pharmaceuticals, Inc. (LXRX-NASDAQ) is a biotech company that many have not heard of, and those who do know it may have a painful history from it. Anyone who got in the stock over…
On tonight’s Mad Money on CNBC, Jim Cramer had his normal ‘Speculation Friday’ and talked CV Therapeutics (CVTX) for a speculative biotech in with Acadia (ACAD) and Nastech (NSTK). Cramer said CVTX is a…
Dendreon (DNDN) has seen a lot of the old hyperactive trading volume come out of the stock now that it is post-FDA panel review and post-ASCO. The stock has barely traded 2 million shares…
GlaxoSmithKline (GSK-NYSE) has been under significant pressure of late because of the New England Journal of Medicine showing greatly increased risks of a heart attack for diabetes patients that have taken AVANDIA. The news…
Stock Tickers: MRK, PFE, JNJ, GSK, SGP, LLY, WYE, NVS, NVO On tonight’s MAD MONEY on CNBC, Jim Cramer said he keeps getting asked about Big Pharma drug stocks. He’d rather focus on farms,…
Some new data is helping two small biotech stocks today at the Alzheimer’s Association International Conference on Prevention of Dementia in Washington, DC. The latest figure showed 26.6 million people worldwide are living with…
This morning shares of Genentech (DNA-NYSE) are trading up 1.3% at just under $76.00 after a Deutsche Bank upgrade on the stock. Shares closed at $74.90 yesterday and even traded as low as $74.32…
Dendreon (DNDN-NASDAQ) announced this morning that it did price its $75 million in convertible senior subordinated notes due 2014 via a Rule 144A private placement. The interest rate is merely 4.75%, and here is…
Cramer has a speculative little drug stock that keeps getting thrown to him in the Lightning Round: Acadia Pharmaceuticals (ACAD). Cramer thinks now is the time that you can buy Acadia. It trades entirely…
Amgen (AMGN) is paying a hefty sum to diversify its Aranesp and Epogen franchises. The company is acquiring developmental-stage Ilypsa, a biotech company based in San Francisco that focuses on kidney disease care, for…
Shares of Dendreon (DNDN) are trading down some 7% pre-market after the company announced that it was going to offer $75 million in convertible senior subordinated notes that are due in 2014. The offering…
Banc of America has noted that yesterday’s ‘positive data’ is actually not new and that the interim data will not be available until the second half of 2008. Mitchell Gold, MD/PhD/CEO of Dendreon, detailed…
Dendreon (DNDN-NASDAQ) is benefitting from something that become thought of as a low probability event: an FDA that buckled at least a little to peer pressure. It has received confirmation that the FDA will…
This weekend we have the mother of all future cancer treatment conferences: ASCO, or The American Society of Clinical Oncology. Cancer stocks in the last few weeks have been seeing a muted response ahead…
Novacea (NOVC-NASDAQ) is seeing its shares up more than 70% after signing a pact with Schering-Plough (SGP-NYSE) over the development and commercialization of Asentar for the treatment of prostate cancer. Novacea will receive an…